Wake-promoting compound validated

May 29, 2017

Narcolepsy, a serious sleep disorder in which patients often fall asleep uncontrollably, has been incurable because no effective therapeutic agents are available to date. Recent findings by Japanese scientists in the sleep institute may shed light on this challenging problem.

Narcolepsy is characterized by excessive daytime sleepiness (sleep attacks), sudden loss of muscle tone often triggered by emotion (called cataplexy), vivid hallucinations and sleep paralysis, and frequent disruption of night-time sleep. Only symptomatic therapies, such as amphetamine-like psychostimulants, are currently available. The disease is caused by a selective loss of neurons producing the neuropeptide orexin, which plays a central role in maintaining wakefulness. Orexin itself is effective to ameliorate narcoleptic symptoms in model animals when directly injected in the brain, but it is blocked at the blood-brain barrier (BBB) when peripherally administered and cannot bind to its brain receptors. Therefore, small compounds that penetrate the BBB and mimic the function of orexin are desirable as therapeutic agents.

Researchers in the International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, have been trying to develop compounds that promote wakefulness and remedies narcolepsy, and they succeeded in synthesizing YNT-185 (reported in J Med Chem in 2015, see below for reference), a non-peptide, selective and potent agonist for the orexin type-2 receptor. In the current study, a research group led by Yoko Irukayama-Tomobe, Yasuhiro Ogawa, Hiromu Tominaga and Masashi Yanagisawa, further examined the pharmacological effect of YNT-185, and verified that peripherally administered YNT-185 penetrates BBB and significantly induces wakefulness, as well as ameliorates narcoleptic symptoms in mouse models. No desensitization was observed after repeated administrations. They also found that daily administrations of YNT-185 prevented increase in the body weight; indeed, narcoleptic patients (and mice) tend to be obese. Their findings provide a proof-of-concept for the treatment of narcolepsy.

Furthermore, the administration of YNT-185 also promotes wakefulness in normal mice without any immediate sleep rebounds. "This compound might also be useful in the treatment of the excessive sleepiness caused by other causes, such as depression, side effects of drugs, jet lag and shift work," said Yanagisawa. "Additionally, it might be effective in preventing the metabolic syndrome." They are now trying to refine YNT-185 to further improve potency and bioavailability. A miracle drug for narcolepsy and other sleep disorders may be born in the near future.
-end-


University of Tsukuba

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.